Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

References

• FerlayJAutierPBoniolMHeanueMColombetMBoylePEstimates of the cancer incidence and mortality in Europe in 2006Ann Oncol200718358159217287242
   PubMed Web of Science ®Google Scholar
• HerbstRSHeymachJVLippmanSMLung cancerN Eng J Med20083591313671380
   PubMed Web of Science ®Google Scholar
• ReungwetwattanaTWerohaSJMolinaJROncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC)Clin Lung Cancer201213425226622154278
   PubMed Web of Science ®Google Scholar
• D’AddarioGFruhMReckMBaumannPKlepetkoWFelipEMetastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5116119
   PubMed Web of Science ®Google Scholar
• BlackhallFHShepherdFAAlbainKSImproving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: a realistic goal?Treat Respir Med200542718415813659
   PubMedGoogle Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin– paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• WellsAEGF receptorInt J Biochem Cell Biol199931663764310404636
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJThe EGF receptor family as targets for cancer therapyOncogene200019566550656511426640
   PubMed Web of Science ®Google Scholar
• SunSSchillerJHGazdarAFLung cancer in never smokers – a different diseaseNat Rev Cancer200771077879017882278
   PubMed Web of Science ®Google Scholar
• SubramanianJGovindanRLung cancer in never smokers: a reviewJ Clin Oncol200725556157017290066
   PubMed Web of Science ®Google Scholar
• LadanyiMPaoWLung adenocarcinoma: guiding EGFR-targeted therapy and beyondMod Pathol200821Suppl 2S16S2218437168
   PubMed Web of Science ®Google Scholar
• WeinsteinIBCancer. Addiction to oncogenes – the Achilles heal of cancerScience20022975578636412098689
   PubMed Web of Science ®Google Scholar
• SawyersCLThe cancer biomarker problemNature2008452718754855218385728
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer2010101176077420966921
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• BaselgaJAverbuchSDZD1839 (“Iressa”) as an anticancer agentDrugs200060Suppl 1334011129170
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• TakedaKHidaTSatoTRandomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203)J Clin Oncol201028575376020038730
   PubMed Web of Science ®Google Scholar
• ZhangLMaSSongXGefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trialLancet Oncol201213546647522512843
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib vs docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• YamamotoNNishiwakiYNegoroSDisease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patientsJ Thorac Oncol2010571042104720453692
   PubMed Web of Science ®Google Scholar
• LeeDHParkKKimJHRandomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapyClin Cancer Res20101641307131420145166
   PubMed Web of Science ®Google Scholar
• CuferTVrdoljakEGaafarRErensoyIPembertonKSIGN Study GroupPhase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancerAnticancer Drugs2006174:40140916549997
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• SimonGRExtermannMChiapporiAPhase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderCancer200811292021202918300255
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• LeeSMKhanIUpadhyaySFirst-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trialLancet Oncol201213111161117023078958
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• CoudertBCiuleanuTParkKSurvival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyAnn Oncol201223238839421610154
   PubMed Web of Science ®Google Scholar
• MillerVAO’ConnorPSohCATLAS InvestigatorsA randomized, double-blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastasic non-small cell lung cancer [abstract]J Clin Oncol200927Suppl 18LBA8002
   Web of Science ®Google Scholar
• PerolMChouaidCPerolDRandomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin–gemcitabine induction chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol201230283516352422949150
   PubMed Web of Science ®Google Scholar
• GridelliCCiardielloFGalloCFirst-line erlotinib followed by second-line cisplatin–gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialJ Clin Oncol201230243002301122778317
   PubMed Web of Science ®Google Scholar
• CiuleanuTStelmakhLCicenasSEfficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyLancet Oncol201213330030822277837
   PubMed Web of Science ®Google Scholar
• WuYLZhouCChengYErlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)Ann Oncol1142012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• KosakaTYatabeYEndohHAnalysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibClin Cancer Res200612195764576917020982
   PubMed Web of Science ®Google Scholar
• TamboriniEPriclSNegriTFunctional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patientsOncogene200625456140614616751810
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA200810562070207518227510
   PubMed Web of Science ®Google Scholar
• ChmieleckiJFooJOxnardGROptimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingSci Transl Med201139090ra59
   PubMed Web of Science ®Google Scholar
• BruggerWThomasMEGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatmentLung Cancer20127712822281074
   PubMed Web of Science ®Google Scholar
• YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
   PubMed Web of Science ®Google Scholar
• SunYShiYZhangLA randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN) [abstract]J Clin Oncol201129 Suppl7522
   Google Scholar
• HeymachJVPaz-AresLDe BraudFRandomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancerJ Clin Oncol200826335407541518936474
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialLancet Oncol201011761962620570559
   PubMed Web of Science ®Google Scholar
• LeeJSHirshVParkKVandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)J Clin Oncol201230101114112122370318
   PubMed Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAPhase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol20112981059106621282542
   PubMed Web of Science ®Google Scholar
• RamalingamSSBlackhallFKrzakowskiMRandomized phase II study of dacomitinib (PF-00299804), an irreversible panhuman epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerJ Clin Oncol201230273337334422753918
   PubMed Web of Science ®Google Scholar
• PietanzaMCLynchTJJrLaraPNJrXL647 – a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinibJ Thorac Oncol20127121922622011666
   PubMed Web of Science ®Google Scholar
• AdjeiAAMolinaJRMandrekarSJPhase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancerClin Cancer Res20071392684269117473200
   PubMed Web of Science ®Google Scholar
• PriceKAAzzoliCGKrugLMPhase II trial of gefitinib and everolimus in advanced non-small cell lung cancerJ Thorac Oncol20105101623162920871262
   PubMed Web of Science ®Google Scholar
• HanJYLeeSHYooNJA randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancerClin Cancer Res20111761553156021411446
   PubMed Web of Science ®Google Scholar
• BuchananFGWangDBargiacchiFDuBoisRNProstaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptorJ Biol Chem200327837354513545712824187
   PubMed Web of Science ®Google Scholar
• AgarwalaAFisherWBruetmanDGefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology GroupJ Thorac Oncol20083437437918379355
   PubMed Web of Science ®Google Scholar
• SpigelDRBurrisHA3rdGrecoFARandomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerJ Clin Oncol201129182582258921576636
   PubMed Web of Science ®Google Scholar
• GridelliCMorgilloFFavarettoASorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II studyAnn Oncol20112271528153421212155
   PubMed Web of Science ®Google Scholar
• ScagliottiGVKrzakowskiMSzczesnaASunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trialJ Clin Oncol201230172070207822564989
   PubMed Web of Science ®Google Scholar
• AltorkiNLaneMEBauerTPhase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerJ Clin Oncol201028193131313720516450
   PubMed Web of Science ®Google Scholar
• DyGKInfanteJREckhardtSGPhase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibInvest New Drugs1182012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• SequistLVvon PawelJGarmeyEGRandomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerJ Clin Oncol201129243307331521768463
   PubMed Web of Science ®Google Scholar
• OuSHGovindanREatonKDPhase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]J Clin Oncol201230 Suppl2610
   Google Scholar
• ZappaFDroegeCBetticherDBevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)Lung Cancer201278323924423009726
   PubMed Web of Science ®Google Scholar
• HerbstRSAnsariRBustinFEfficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialLancet201137797801846185421621716
   PubMed Web of Science ®Google Scholar
• RiggsHJalalSIBaghdadiTAErlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with non-squamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77Clin Lung Cancer10242012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• SmithDAConklingPRichardsDAEfficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy [abstract]J Clin Oncol201230 Supple18047
   Google Scholar
• WeickhardtADoebeleROtonAA phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancerJ Thorac Oncol20127241942622237261
   PubMed Web of Science ®Google Scholar
• RamalingamSSSpigelDRChenDRandomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancerJ Clin Oncol201129344574458022025157
   PubMed Web of Science ®Google Scholar
• PapadimitrakopoulouVASoriaJCJappeAJehlVKlimovskyJJohnsonBEEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancerJ Thorac Oncol20127101594160122968184
   PubMed Web of Science ®Google Scholar
• Clement-DucheneCNataleRBJahanTA phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerLung Cancer2012781576222809813
   PubMed Web of Science ®Google Scholar
• LynchTJFentonDHirshVA randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancerJ Thorac Oncol2009481002100919633475
   PubMed Web of Science ®Google Scholar
• WittaSEJotteRMKonduriKRandomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapyJ Clin Oncol201230182248225522508830
   PubMed Web of Science ®Google Scholar
• JanjigianYYGroenHJHornLActivity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib [abstract]J Clin Oncol201129 Suppl7525
   Web of Science ®Google Scholar
• EngelmanJAJannePAMechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res200814102895289918483355
   PubMed Web of Science ®Google Scholar